切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2021, Vol. 15 ›› Issue (06) : 432 -436. doi: 10.3877/cma.j.issn.1674-0793.2021.06.007

论著

甲状腺乳头状癌SLeX和Gal-3表达的临床病理意义
聂阿娜1, 尚培中1,(), 苗建军1, 王金1, 李伟2   
  1. 1. 075000 张家口,陆军第81集团军医院普通外科
    2. 075000 张家口,陆军第81集团军医院检验病理科
  • 收稿日期:2021-01-28 出版日期:2021-12-01
  • 通信作者: 尚培中
  • 基金资助:
    张家口市大健康和生物医疗专项重点研发计划项目(2021065D)

Clinicopathological study on the expression of SLeX and Gal-3 in papillary thyroid carcinoma

A 'na Nie1, Peizhong Shang1,(), Jianjun Miao1, Jin Wang1, Wei Li2   

  1. 1. Department of General Surgery, the 81st Group Army Hospital of PLA, Zhangjiakou 075000, China
    2. Department of Pathological and Medical Laboratory, the 81st Group Army Hospital of PLA, Zhangjiakou 075000, China
  • Received:2021-01-28 Published:2021-12-01
  • Corresponding author: Peizhong Shang
引用本文:

聂阿娜, 尚培中, 苗建军, 王金, 李伟. 甲状腺乳头状癌SLeX和Gal-3表达的临床病理意义[J/OL]. 中华普通外科学文献(电子版), 2021, 15(06): 432-436.

A 'na Nie, Peizhong Shang, Jianjun Miao, Jin Wang, Wei Li. Clinicopathological study on the expression of SLeX and Gal-3 in papillary thyroid carcinoma[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2021, 15(06): 432-436.

目的

探讨SLeX和Gal-3表达与甲状腺乳头状癌(PTC)临床病理指标的关系。

方法

收集2017年5月至2020年12月间陆军第81集团军医院收治的120例PTC手术切除标本,应用EliVisionTM plus免疫组织化学二步法检测SLeX和Gal-3在癌组织及癌旁甲状腺组织中的表达,分析PTC组织中的表达与患者5项临床病理指标的关系。

结果

癌组织SLeX和Gal-3阳性率分别为67.5%和90.8%,癌旁甲状腺组织分别为6.7%和16.7%,差异均有统计学意义(P<0.001)。依据患者年龄分组,组间SLeX阳性率差异无统计学意义;依据TI-RADS分级[(4级+5级)vs6级]、TNM分期[(T1期+T2期)vs T3期]、有无癌浸润、有无淋巴结转移分组,组间SLeX阳性率差异均有统计学意义(P<0.05)。Gal-3表达阳性率在患者年龄、TI-RADS分级、TNM分期3项指标分组的各组间差异均无统计学意义,在癌浸润、淋巴结转移各组间差异均有统计学意义(P<0.05)。120例患者SLeX和Gal-3共阳性率为65.8%,共阴性率为7.5%,两者表达呈正相关(r=0.32,P<0.05)。

结论

SLeX表达上调预示TI-RADS分级高、癌组织分期晚,SLeX和Gal-3高水平表达均与PTC浸润性及转移性密切相关。

Objective

To investigate the expression changes of SLeX and Gal-3 in papillary thyroid carcinoma (PTC) and the relationship with clinicopathologic parameters.

Methods

A retrospective study of 120 continuous patients with PTC who underwent resection from May 2017 to December 2020 was conducted. The expressions of SLeX and Gal-3 were detected in 120 pieces of primary PTC tissue and 30 pieces of adjacent carcinoma tissue by EliVisionTM plus two-step immunohistochemical method. The relationships between the expressions of SLeX and Gal-3 and the clinicopathologic parameters including patient age, TI-RADS grading, TNM staging,carcinomatous infiltration, lymph node metastasis were studied.

Results

The differences of positive rates of SLeX and Gal-3 between primary PTC tissue (67.5%, 90.8% respectively) and adjacent carcinoma tissue (6.7%, 16.7% respectively) were statistically significant (both P<0.001). The expressions of SLeX had not statistically significant in the groups of different ages. The SLeX expression significantly correlated with the TI-RADS grading, TNM stages, carcinomatous infiltration, lymph node metastasis (all P<0.05). The expressions of Gal-3 had not statistically significant in the groups of different ages, TI-RADS grading, TNM stages. The Gal-3 expression significantly correlated with the carcinomatous infiltration, lymph node metastasis (both P<0.05). The rate of both positive expressions was 65.8%, and both negative expressions was 7.5%. There was a positive correlation between the expressions of SLeX and Gal-3 in PTC tissue (r=0.32, P<0.05).

Conclusion

The up-regulated SLeX expression may hint high TI-RADS grading and late TNM stages. High-level expressions of SLeX and Gal-3 in PTC are closely correlated with the progress of carcinomatous infiltration and lymph node metastasis.

表1 SLeX和Gal-3在甲状腺乳头状癌组织及癌旁组织中的表达比较[例(%)]
图1 SLeX在PTC组织中强阳性表达(EliVision ×100)
图2 SLeX在癌旁甲状腺组织中阴性表达(EliVision ×100)
图3 Gal-3在PTC组织中强阳性表达(EliVision ×100)
图4 Gal-3在癌旁甲状腺组织中阴性表达(EliVision ×100)
表2 SLeX和Gal-3表达与甲状腺乳头状癌患者临床病理指标的关系[例(%)]
[1]
吴超杰,乔高昂,笪东祝, 等. 甲状腺术中甲状旁腺识别技术的转化研究进展[J/CD]. 中华普通外科学文献(电子版), 2020, 14(1): 68-71.
[2]
郑福庆,张立永,王波, 等. 甲状腺乳头状癌颈侧区淋巴结转移的危险因素研究进展[J/CD]. 中华普通外科学文献(电子版), 2020, 14(5): 384-387.
[3]
王勇,王玲. 甲状腺癌术后碘131联合甲状腺激素应用效果分析[J/CD]. 中华普外科手术学杂志(电子版), 2020, 14(6): 616-619.
[4]
王涛,柳桢,左道宏, 等. 肿瘤异常蛋白在甲状腺乳头状癌中的表达及影响因素分析[J]. 中华内分泌外科杂志, 2020, 14(2): 133-138.
[5]
宋创业,严丽,孟艳林, 等. 甲状腺癌发生发展及预后的相关影响因素[J/CD]. 中华普通外科学文献(电子版), 2020, 14(1): 72-75.
[6]
中华人民共和国国家卫生健康委员会. 甲状腺癌诊疗规范(2018年版)[J/CD]. 中华普通外科学文献(电子版), 2019, 13(1): 1-15.
[7]
王首星,尚培中. 结直肠癌Lewis-Selectin转移途径与西咪替丁抗癌治疗研究进展[J]. 中国普外基础与临床杂志, 2010, 17(7): 760-764.
[8]
Starzonek S, Maar H, Labitzky V, et al. Systematic analysis of the human tumor cell binding to human vs. murine E- and P-selectin under static vs. dynamic conditions[J]. Glycobiology, 2020, 30(9): 695-709.
[9]
Cohen EN, Fouad TM, Lee BN, et al. Elevated serum levels of sialyl Lewis X (sLex) and inflammatory mediators in patients with breast cancer[J]. Breast Cancer Res Treat, 2019, 176(3): 545-556.
[10]
Ferreira IG, Carrascal M, Mineiro AG, et al. Carcinoembryonic antigen is a sialyl Lewis x/a carrier and an Eselectin ligand in nonsmall cell lung cancer[J]. Int J Oncol, 2019, 55(5): 1033-1048.
[11]
Doi N, Ino Y, Angata K, et al. Clinicopathological significance of core 3 O-glycan synthetic enzyme, β1, 3-N-acetylglucosaminyltransferase 6 in pancreatic ductal adenocarcinoma[J]. PloS One, 2020, 15(11): e0242851.
[12]
Mai KT, Ford JC, Yazdi HM, et al. Immunohistochemical study of papillary thyroid carcinoma and possible papillary thyroid carcinoma-related benign thyroid nodules[J]. Pathol Res Pract, 2000, 196(8): 533-540.
[13]
谷化平,李德炳,张正猛, 等. P53和Sialyl Lewis-X表达与甲状腺乳头状癌侵袭转移的关系[J]. 西安交通大学学报(医学版), 2005, 26(1): 71-73.
[14]
Low S, Sakai Y, Hoshino H, et al. High endothelial venule-like vessels and lymphocyte recruitment in diffuse sclerosing variant of papillary thyroid carcinoma[J]. Pathology, 2016, 48(7): 666-674.
[15]
郭宏义,宁亚文,李文龙, 等. 细胞角蛋白19、半乳糖凝集素3、HBME-1和BRAF V600E表达在甲状腺结节的临床应用价值[J/CD]. 中华普通外科学文献(电子版), 2020, 14(5): 331-335.
[16]
Yu W, Ma B, Zhao W, et al. The combination of circRNA-UMAD1 and Galectin-3 in peripheral circulation is a co-biomarker for predicting lymph node metastasis of thyroid carcinoma[J]. Am J Transl Res, 2020, 12(9): 5399-5415.
[17]
Cho H, Kim JY, Oh YL. Diagnostic value of HBME-1, CK19, Galectin 3, and CD56 in the subtypes of follicular variant of papillary thyroid carcinoma[J]. Pathol Int, 2018, 68(11): 605-613.
[18]
De Rose F, Braeuer M, Braesch-Andersen S, et al. Galectin-3 targeting in thyroid orthotopic tumors opens new ways to characterize thyroid cancer[J]. J Nucl Med, 2019, 60(6): 770-776.
[19]
Song S, Kim H, Ahn SH, et al. Role of immunohistochemistry in fine needle aspiration and core needle biopsy of thyroid nodules[J]. Clin Exp Otorhinolar, 2019, 12(2): 224-230.
[20]
南润玲,尚培中,王金, 等. 甲状腺乳头状癌术中纳米炭示踪对淋巴结清扫及甲状旁腺保护的临床意义[J/CD]. 中华普通外科学文献(电子版), 2018, 12(1): 36-39.
[21]
Yu W, Ma B, Zhao W, et al. The combination of circRNA-UMAD1 and Galectin-3 in peripheral circulation is a co-biomarker for predicting lymph node metastasis of thyroid carcinoma[J]. Am J Transl Res, 2020, 12(9): 5399-5415.
[1] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[2] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[3] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[4] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[5] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[6] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[7] 陈樽, 王平, 金华, 周美玲, 李青青, 黄永刚. 肌肉减少症预测结直肠癌术后切口疝发生的应用研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 639-644.
[8] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[9] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[10] 陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[11] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[12] 董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[13] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[14] 谭瑞义. 小细胞骨肉瘤诊断及治疗研究现状与进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 781-784.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要